Status: Available
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
Trial details
Age: 2+Biological sex: AllType: Expanded AccessSponsor: Eisai Inc.Updated: Jan 30, 2025Locations: 22
Eligibility criteria
Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North... [+3]